The immune response of mice and cynomolgus monkeys to macaque mucin 1- mannan

Vaccine

Volumn 18, Issue 28, 2000, Pages 3297-3309

  Vaughan, Hilary A ^a   Ho, Deborah W M ^a   Karanikas, Vaios ^a   Sandrin, Mauro S ^a   McKenzie, Ian F C ^a   Pietersz, Geoffrey A ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Antibodies; CTL; Non human primates; Vaccination

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANNAN; MUCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IMMUNE RESPONSE; MACACA; MONKEY; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL;

EID: 0034257109     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00143-2     Document Type: Article

References (43)

1. Melief C.J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 58:1992;143-175.
2. Boon T., Cerottini J.-C., Van den Eynde B., Van den Bruggen P., Van Pel A. Tumor antigen recognised by T lymphocytes. Ann. Rev. Immunol. 12:1994;337-365.
3. Apostolopoulos V., McKenzie I.F.C. Cellular mucins: Targets for immunotherapy. Crit. Rev. Immunol. 14:1994;293-309.
4. Finn O.J., Jerome K.R., Henderson R.A., Pecher G., Domenech N., Magarian-Blander J., Barret-Boyes S.M. MUC-1 epithelial tumour mucin-based immunity and cancer vaccines. Immunol. Rev. 154:1995;61-89.
5. Gendler S.J., Spicer A.P. Epithelial mucin genes. Ann. Rev. Physiol. 57:1995;607-634.
6. Taylor-Papadimitriou J., Finn O.J. Biology, biochemistry and immunology of carcinoma-associated mucins. Immunology Today. 18:1997;105-107.
7. Ligtenberg M.L., Buijsg F., Vos H.L., Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52:1992;2318-2324.
8. Regimbald L.H., Pilarski L.M., Longnecker B.M., Reddish M.A., Zimmermann G., Hugh J.C. The breast mucin MUC1 as a novel adhesion ligand for endothelial intracellular adhesion molecule 1 in breast cancer. Cancer Res. 56:1996;4244-4249.
9. Rughetti A., Turchi V., Ghetti C.A., Scambia G., Panici P.B., Ronucci G., Mancuso S., Fratti L., Nutti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53:1993;2457-2459.
10. Kotera Y., Fontenot J.D., Pecher G., Metzgar R.S., Finn O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54:1994;2856-2860.
11. Barnd D.L., Lan M.S., Metzgar R.S., Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 86:1989;7159-7163.
12. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., Mckenzie I.F.C., Bast R.C. Jr, Finn O.J. Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:1991;2908-2916.
13. Jerome K.R., Domenech N., Finn O.J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognise EBV-immortalised B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151:1993;1654-1662.
14. Ioaniddes C.G., Fisk B., Jerome K.R., Irmura T., Wharton T.J., Finn O.J. Cytotoxic T cells from ovarian malignant tumors can recognise polymorphic epithelial mucin core peptides. J. Immunol. 151:1994;3693-3703.
15. Takahashi T., Makiguchi Y., Hinoda Y., Kakiuchi H., Nakagawa N., Iami K., Yachi A. Expression of MUC1 on myeloma cells and induction of HLA unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 153:1994;2102-2109.
16. Domenech N., Henderson R.A., Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumour antigen mucin. J. Immunol. 155:1995;4766-4774.
17. Bohm C.M., Mulder M.C., Zennadi R., Notter M., Schmitt-Graff A., Finn O.J., Taylor-Papadimitriou J., Stein H., Clausen H., Riecken E.O., Hanski C. Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand. J. Immunol. 46:1997;27-34.
18. 2 responses. Proc. Natl. Acad. Sci. USA. 92:1995;10,128-10,132.
19. Apostolopoulos V., Pietersz G.A., McKenzie I.F.C. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine. 14:1996;930-938.
20. Kennedy R.C., Shearer M.H., Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine. 15:1997;903-908.
21. Siddiqui J., Abe M., Hayes E., Yunis E., Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA. 85:1998;2320-2323.
22. Vaughan H.A., Oldenburg K.R., Gallop M.A., Atkin J.D., McKenzie I.F.C. Recognition of an octapeptide sequence by multiple Galα(1,3)Gal-binding proteins. Xenotransplantation. 3:1996;18-23.
23. Xing P.X., Reynolds K., Tjandra J.J., Tang X.-L., McKenzie I.F.C. Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res. 50:1990;89-96.
24. + cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 151:1993;5096-5105.
25. National Health, Medical Research Council; Commonwealth Scientific, Industrial Research Organisation, Australian Agricultural Council. Australian code of practise for the care and use of animals for scientific purposes. 1990;Australian Government Publishing Service, Canberra.
26. Graham R.A., Burchell J.M., Beverley P., Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer. 65:1996;664-670.
27. Vaughan H.A., Ho D.W., Karanikas V.A., Ong C.S., Hwang L.A., Pearson J.M., McKenzie I.F.C., Pietersz G.A. Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates. Vaccine. 17:1999;2740-2752.
28. Pietersz G.A., Li W., Popovski V., Caruana J., Apostolopoulos V., McKenzie I.F.C. Parameters for using mannan-MUC1 fusion protein (MFP) to induce cellular immunity. Cancer Immunology Immunotherapy. 45:1998;321-326.
29. Spicer A.P., Duhig T., Chilton B.S., Gendler S.J. Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mammalian Genome. 6:1995;886-888.
30. Spicer A.P., Parry G., Patton S., Gendler S.J. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J. Biol. Chem. 206:1991;15,099-15,109.
31. Clausen H., Bennett E.P. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology. 6:1996;635-646.
32. Vos de H.L. Vries Y., Hilkens J. The mouse episialin (MUC1) gene and its promoter. Biochem. Biophys. Res. Commun. 181:1991;121-130.
33. Lancaster C.A., Peat N., Duhig T., Wilson D., Taylor-Papadimitriou J., Gendler S.M. Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem. Biophys. Res. Commun. 173:1990;1019-1029.
34. Hareuveni M., Tsarfaty I., Zaretsky J., Kotkes P., Horev J., Zrihan S., Weiss M., Green S., Lathe R., Keydar I., Wreschner D. A transcribed gene, containing variable number of tandem repeats, codes for a human epithelial tumor antigen. CDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. Eur. J. Biochem. 189:1990;475-486.
35. Patton S., Huson G.E., Jenness R., Vaucher Y. Differences between individuals in high-molecular weight glycoproteins from mammary epithelia of several species. Biochim. Biophys. Acta. 980:1989;333-338.
36. Karanikas V., Hwang L., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H.A., Xing P.-X., Jamieson G., Pietersz G.A., Tait B.D., Broadbent R., Thynne G., McKenzie I.F.C. Antibody and T cell responses of patients with adenocarcinoma immunised with mannan-MUC1 fusion protein. J. Clin. Invest. 100:1997;2783-2792.
37. Pietersz G.A., Li W., Osinski C., Apostolopoulos V., McKenzie I.F.C. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine. 18:2000;2059-2071.
38. Nakao M., Yamana H., Iami Y., Toh Y., Toh U., Kimura A., Yanoma S., Kakegawa T., Itoh K. HLA A2601-restricted CTL's recognise a peptide anigen expressed on squamous cell carcinoma. Cancer Res. 55:1995;4248-4252.
39. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M., Hartman M., Anholts J.D.H., Schreuder G.M.T., Bram Ter Harmsel W., Jan Fleuren G., Trimbos B.J., Kast W.M., Melief C.J.M. Occasional memory cytotoxic T cell responses of patients with papilloma virus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res. 56:1996;582-588.
40. Pass H.A., Schwarz S.L., Wunderlich J.R., Rosenberg S.A. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4:1998;316-323.
41. Tabata T., Hazama S., Yoshino S., Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am. J. Surg. 177:1999;203-208.
42. Apostolopoulos V., Osinski C., McKenzie I.F.C. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch responses from cellular to humoral. Nat. Med. 4:1998;315-320.
43. Galili T.U., Clark M.R., Shohet S.B., Buehler J., Macher B.A. Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc. Natl. Acad. Sci. USA. 84:1987;1369-1373.